The 4 Phases Of Clinical Trials: How New Treatments Move From Lab To Clinic (What To Expect In 2026)

what are the 4 phases of clinical trials
Phase Purpose Participants Typical length Share moving on Planning use
Phase 1 Safety and dosage 20 to 100 healthy volunteers or people with the condition Several months Approximately 70% Treat as an early safety signal, not proof the product works.
Phase 2 Efficacy and side effects Up to several hundred people with the condition Several months to 2 years Approximately 33% Promising but still unconfirmed; most candidates stop here or earlier.
Phase 3 Efficacy and monitoring of adverse reactions 300 to 3,000 volunteers with the condition 1 to 4 years Approximately 25-30% The strongest evidence available before approval.
Phase 4 Safety and efficacy after approval Several thousand volunteers with the condition Runs after approval Not applicable: the drug is already approved Useful for judging long-term safety and real-world use.

These figures come from the FDA’s clinical research step of the drug development process.

What are the 4 phases of clinical trials? Phase 1 tests safety and dose, Phase 2 tests efficacy and side effects, Phase 3 confirms benefit in large groups, and Phase 4 follows safety after FDA approval.

Knowing the phase tells you how much evidence sits behind a product. For a wider checklist on weighing studies, see how to tell if a health study is reliable.

What the phase tells you about a product’s evidence

A trial phase is a label for how far a treatment’s evidence has progressed. The FDA describes clinical trials as a typical series from early, small-scale Phase 1 studies to late-stage, large-scale Phase 3 studies. When you read a headline about a new treatment, the phase is the first thing to check, because it shows what question the study could actually answer.

Several printed sheets with numbered phase graphics, a yellow pencil, and a dark green notebook lie on a wooden desk.
  • Phase 1 only: The study asked whether the drug is safe and what dose range is tolerable. It was not designed to show benefit, so be cautious about any claim that the treatment works.
  • Phase 2 results: These are the first efficacy and side-effect data in people who have the condition. They are worth following, but they come from a limited group and many drugs do not progress beyond this point.
  • Completed Phase 3: This is the stage where large groups test efficacy and monitor adverse reactions. Before filing a marketing application, a developer must have adequate data from two large, controlled clinical trials, so this is the evidence regulators weigh.
  • Phase 4 data: These come from the period after approval and speak to long-term safety and use outside the original trial setting. They are the best guide to how a drug behaves once many people take it.
  • A “trial” with no phase named: Ask which phase it was and how many people took part. Without those two details you cannot judge how much weight the result deserves.

The practical rule is to match your confidence to the phase. Early-phase success is a reason for interest, not for changing a treatment decision. Next, here is what each phase involves.

What happens in each phase

Each phase asks a different question, and the participant group changes as the questions get harder. Before any of it starts, the sponsor must submit an Investigational New Drug (IND) application to the FDA before beginning clinical research.

Phase 1: safety and dose range

Phase 1 trials are concerned primarily with establishing a new drug’s safety and dose range in 20 to 100 healthy volunteers. The FDA adds that in most cases 20 to 80 healthy volunteers or people with the condition take part. A Phase 1 trial takes several months to complete, and about 70 percent of experimental drugs pass this stage. Work that happens before human testing, such as laboratory models, is compared in Ex Vivo Vs In Vitro: How They Differ And When To Use Each (Practical Guide 2026) – Testpledge.

Phase 2: efficacy and side effects

In Phase 2, researchers give the drug to people who have the condition and look at efficacy and side effects. The FDA puts participation at up to several hundred people, while the University of Cincinnati describes approximately 100 to 300 volunteers. This phase may last from several months to two years. Most Phase II studies are randomized, meaning subjects are assigned randomly to groups. To see how comparison groups and expectation can colour results, read Placebo Effect Examples: 9 Real-World Cases That Reveal How Expectation Shapes Health (2026 Update) – Testpledge. Approximately 33% of drugs move on from here.

Phase 3: confirming efficacy at scale

Phase 3 enrolls 300 to 3,000 volunteers who have the disease or condition, according to the FDA. The university source notes that these studies run at multiple centers with several hundred to several thousand patients. The FDA lists the purpose as efficacy and monitoring of adverse reactions, over a span of 1 to 4 years. Roughly 25-30% of drugs move on. Once a Phase III study is completed, a pharmaceutical company can request FDA approval to market the drug.

Phase 4: after approval

Phase 4 trials are carried out once the drug or device has been approved by the FDA, with several thousand volunteers who have the condition. The UNC drug development program explains that Phase IV clinical trials are used to assess the long-term safety profiles of drugs and real-world efficacy after market approval. Because the group is larger and the timeline longer than in earlier phases, this is where less common effects can surface.

Participants and timing

Participant numbers grow with each phase, and so does the commitment. The ranges in the table are ranges, not targets: a Phase 1 trial can sit anywhere from 20 to 100 people, and a Phase 3 trial anywhere from 300 to 3,000. A small Phase 3 trial is not automatically weaker than a large one, but size determines how precisely an effect can be estimated and how many adverse reactions can be observed.

Timing follows the same pattern. Phase 1 takes several months, Phase 2 several months to 2 years, and Phase 3 1 to 4 years. Those spans cover the trial itself, so a product’s overall route to the market is longer than any single figure. A news story about a drug that reached Phase 2 recently is a snapshot, not a forecast of approval.

The attrition figures give the same message. Approximately 70% of drugs move beyond Phase 1, approximately 33% beyond Phase 2 and approximately 25-30% beyond Phase 3. For anyone assessing a product, a drug in Phase 2 has a much lower chance of reaching patients than the same drug already through Phase 3.

Checking where a trial stands

You can check a product’s evidence yourself by searching a public trial registry such as ClinicalTrials.gov for the product name, active ingredient or condition. Look for the phase listed on each study and whether it matches what the product’s marketing implies.

A laptop showing a generic search page. Searching by product name or condition is how most people begin checking a trial’s phase.
  • Search by condition and ingredient: A product name may be a brand, while studies are often listed under the active ingredient.
  • Match the phase to the claim: A claim that a treatment “works” needs support beyond Phase 1, because that phase is aimed at safety and dosage.
  • Compare group size with the table above: A study far below the typical range for its stated phase is worth questioning.
  • Look for approval status: Phase 4 studies only occur after the FDA has approved the drug or device.

Frequently asked questions

Do Phase 1 volunteers always have the condition being studied?

No. The FDA says Phase 1 participants are healthy volunteers or people with the disease or condition, and in most cases the group numbers 20 to 80.

How long does the FDA have to review an IND?

The FDA review team has 30 days to review the original IND submission, which sponsors must file before clinical research begins.

Is Phase 2 harder to pass than Phase 1?

By these figures, yes. Approximately 70% of drugs move past Phase 1, which focuses on safety and dosage, but approximately 33% move past Phase 2, where efficacy and side effects are examined.

Can a company seek approval before Phase 4?

Yes. Phase 4 trials are carried out once a drug has been approved, so a company can request FDA approval after Phase III is completed.